Replies to post #61864 on Avid Bioservices Inc (CDMO)

[Thurly]

Since PPHM's strategy is to pursue the easiest route to approval (2nd line/high unmet need) and then pursue the more difficult approval (frontline/high unmet need), it looks to me like they are,

1. trying to establish the best regimen for the front line phase of NSCLC clinical trials -- which would initiate immediately on a 2nd line approval.

2. aggressively positioning themselves for off-label, front line dosing after they get second line marketing approval.

I agree with those that believe management is in the middle of implementing a clear strategy that is focused on getting their pipeline to market and maximizing their sales potential once they get there.